Tuesday, January 28, 2014

The Motley Fool: The Bristol-Myers Squibb Co. Overreaction Highlights The Dependence On Oncology

After years of the big pharma industry pushing diversification as the solution to its woes, at least one major player is breaking from the pack. Bristol-Myers Squibb (NYSE: BMY  ) is prioritizing its oncology and virology assets, and the company has already staked out some attractive real estate in the immuno-oncology space. While the appeal and potential of immuno-oncology is legitimate, the valuation is already generous and the company's lead on Merck and Roche may not be as strong as the bulls hope.

Please continue here:
The Bristol-Myers Squibb Co. Overreaction Highlights The Dependence On Oncology

No comments: